MDCO » Topics » EXHIBIT INDEX

This excerpt taken from the MDCO 10-Q filed Nov 10, 2008.

EXHIBIT INDEX

 

Exhibit Number

 

Description

 

 

 

2.1†

 

Sale and Purchase Agreement, dated August 4, 2008, between the Company and Curacyte AG (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K/A, filed on November 10, 2008).

 

 

 

31.1

 

Chairman and Chief Executive Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

31.2

 

Chief Financial Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

32.1

 

Chairman and Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

32.2

 

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 


              Confidential treatment requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission

 

48


This excerpt taken from the MDCO 8-K filed Oct 22, 2008.

Exhibit Index

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release dated October 22, 2008 entitled “The Medicines Company Reports Third Quarter 2008 Financial Results”

 

4


This excerpt taken from the MDCO 10-Q filed Aug 11, 2008.
EXHIBIT INDEX

 

Exhibit Number

 

Description

 

 

 

10.1

 

Amended and Restated 2004 Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to our Registration Statement Form S-8, dated July 3, 2008)

 

 

 

10.2

 

Summary of Annual Cash Bonus Plan

 

 

 

31.1

 

Chairman and Chief Executive Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

31.2

 

Chief Financial Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

32.1

 

Chairman and Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

32.2

 

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

45


This excerpt taken from the MDCO 8-K filed Aug 6, 2008.

Exhibit Index

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release dated August 5, 2008 entitled “The Medicines Company’s Acquires CU-2010 and Curacyte Discovery GmbH”

 

4


This excerpt taken from the MDCO 8-K filed Aug 4, 2008.

Exhibit Index

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release dated August 4, 2008 entitled “The Medicines Company’s Cleviprex™ Receives FDA Approval”

 

4


This excerpt taken from the MDCO 8-K filed Jul 23, 2008.

Exhibit Index

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release dated July 23, 2008 entitled “The Medicines Company Reports Second Quarter and First Half 2008 Financial Results and Raises Full Year Top Line Guidance”

 

4


This excerpt taken from the MDCO 8-K filed Jun 3, 2008.

Exhibit Index

 

Exhibit No.

 

Description

 

 

 

10.1

 

The Medicines Company’s Amended and Restated 2004 Stock Incentive Plan (incorporated by reference to Appendix I to the Company’s definitive proxy statement, dated April 29, 2008, for the Company’s 2008 Annual Meeting of Stockholders).

 

 

 

 

 

 

 

 

 

4


This excerpt taken from the MDCO 8-K filed May 28, 2008.

Exhibit Index

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release dated May 28, 2008 entitled “The Medicines Company Receives FDA Review Letter For Angiomax Supplemental Filing”

 

 

4


This excerpt taken from the MDCO 10-Q filed May 12, 2008.
EXHIBIT INDEX

 

Exhibit Number

 

Description

 

 

 

31.1

 

Chairman and Chief Executive Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

31.2

 

Chief Financial Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

32.1

 

Chairman and Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

32.2

 

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

41


This excerpt taken from the MDCO 8-K filed Apr 23, 2008.

Exhibit Index

 

Exhibit No.

 

Description

99.1

 

Press release dated April 23, 2008 entitled “The Medicines Company Reports First Quarter 2008 Financial Results”

 

 

 

 

 

 

 

4


This excerpt taken from the MDCO 8-K filed Feb 13, 2008.

Exhibit Index

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release dated February 13, 2008 entitled “The Medicines Company Reports Full Year and Fourth Quarter 2007 Financial Results”

 

4


This excerpt taken from the MDCO 10-Q filed Nov 8, 2007.

EXHIBIT INDEX

 

Exhibit Number

 

Description

 

 

 

10.1*

 

Termination and Transition Agreement dated July 1, 2007 between the Registrant and Nycomed Danmark ApS

 

 

 

10.2*

 

Distribution Agreement dated July 1, 2007 between the Registrant and Nycomed Danmark ApS

 

 

 

10.3*

 

Services Agreement dated July 1, 2007 between the Registrant and Nycomed Danmark ApS

 

 

 

10.4*

 

Amendment to License Agreement dated July 6, 2007 between the Registrant and AstraZeneca AB.

 

 

 

31.1

 

Chairman and Chief Executive Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

31.2

 

Chief Financial Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

32.1

 

Chairman and Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

32.2

 

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 


*    Portions of the exhibit have been redacted and are subject to a confidential treatment request filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

 

44


This excerpt taken from the MDCO 8-K filed Oct 24, 2007.

Exhibit Index

 

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release dated October 24, 2007 entitled “The Medicines Company Reports Third Quarter 2007 Financial Results”

 

4


This excerpt taken from the MDCO 8-K filed Sep 11, 2007.

Exhibit Index

Exhibit No.

 

Description

 

 

 

99.1

 

Revised Presentation Slides for the Bear Stearns 20th Annual Healthcare Conference on September 10, 2007

 

4



This excerpt taken from the MDCO 8-K filed Sep 10, 2007.

Exhibit Index

Exhibit No.

 

Description

 

 

 

99.1

 

Presentation Slides for the Bear Stearns 20th Annual Healthcare Conference on September 10, 2007

 

4



This excerpt taken from the MDCO 10-Q filed Aug 9, 2007.
EXHIBIT INDEX

Exhibit Number

 

Description

 

 

 

10.1(1)

 

Summary of Board of Director Compensation

 

 

 

10.2(1)

 

Consulting Agreement dated April 6, 2007 between the Registrant and Hiroaki Shigeta

 

 

 

31.1

 

Chairman and Chief Executive Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

31.2

 

Chief Financial Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

32.1

 

Chairman and Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

32.2

 

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 


(1) Filed as an exhibit to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 (File No. 000-31191) and incorporated herein by reference.

42



This excerpt taken from the MDCO 8-K filed Jul 25, 2007.

Exhibit Index

Exhibit No.

 

Description

99.1

 

Press release dated July 25, 2007 entitled “The Medicines Company Reports Second Quarter and First Half 2007 Financial Results”

 

4



This excerpt taken from the MDCO 10-Q filed May 9, 2007.
EXHIBIT INDEX

Exhibit Number

 

Description

 

 

 

10.1

 

Summary of Board of Director Compensation

 

 

 

10.2

 

Consulting Agreement dated April 6, 2007 between the registrant and Hiroaki Shigeta

 

 

 

31.1

 

Chairman and Chief Executive Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

31.2

 

Chief Financial Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

32.1

 

Chairman and Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

32.2

 

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

34



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki